Company intelligence / Profile preview

Bodyport

San Francisco, California, United Statesbodyport.com ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Published clinical results show that Bodyport’s non-invasive monitoring technology predicts heart failure events at twice the rate of conventional care. The FDA-cleared Bodyport Cardiac Scale enables at-home assessment of hemodynamic biomarkers to support early intervention and reduce hospitalizations for patients with chronic cardiac and renal conditions. Ongoing pilot programs with major health systems are evaluating real-world impact on readmissions and care efficiency.

Therapeutic areas: CardiovascularNephrology
Modalities: Device (Bodyport Cardiac Scale)Digital therapeutic platform
Industry: Physiological Monitoring

Partnerships

Geisinger Health System (pilot program for remote heart failure management)

Beyond the preview

Go deeper on Bodyport.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bodyport.

Explore the full profile